John DeFord - Becton Dickinson Executive Vice President, Chief Technology Officer
| BDX Stock | USD 221.90 0.08 0.04% |
President
Dr. John A. DeFordas is Executive Vice President, Chief Technology Officer of the Company. Since the completion of the C. R. Bard, Inc. transaction, DeFord has served as senior vice president of RD for the Interventional Segment at BD. Prior to the acquisition, he served as senior vice president for Science, Technology and Clinical Affairs at Bard. DeFord joined Bard in 2004 as vice president of Science and Technology after serving as a managing director for life science investments with Early Stage Partners, a VC fund. Prior to Early Stage Partners, DeFord was president and CEO of Cook Inc., now known as Cook Medical. DeFord serves on the board of directors of NuVasive and is a member of the executive faculty at the Krannert School of Management and Weldon School of Biomedical Engineering at Purdue University. He received bachelor and master degrees in electrical engineering and a doctorate in electrical and biomedical engineering from Purdue. DeFord is published in multiple scientific journals, holds numerous patents and was recognized with several industry honors.
| Age | 55 |
| Address | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 |
| Phone | 201 847 6800 |
| Web | https://www.bd.com |
Becton Dickinson Management Efficiency
The company has Return on Asset of 0.0325 % which means that on every $100 spent on assets, it made $0.0325 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0563 %, implying that it generated $0.0563 on every 100 dollars invested. Becton Dickinson's management efficiency ratios could be used to measure how well Becton Dickinson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.08 in 2024. Return On Capital Employed is likely to drop to 0.05 in 2024. At this time, Becton Dickinson's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 49.2 B in 2024, whereas Net Tangible Assets are likely to drop (9.1 B) in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Warren Nighan | AngioDynamics | 55 | |
| Mario Wijker | Teleflex Incorporated | 52 | |
| William Burke | Haemonetics | 52 | |
| Jennifer Schneiders | Hologic | 56 | |
| Benjamin Davis | AngioDynamics | 60 | |
| Cameron Hicks | Teleflex Incorporated | 59 | |
| James Leyden | Teleflex Incorporated | 52 | |
| Michelle Basil | Haemonetics | 52 | |
| Andy Polywacz | West Pharmaceutical Services | N/A | |
| Bobby Ghoshal | ResMed Inc | 52 | |
| Annette Favorite | West Pharmaceutical Services | 59 | |
| Chad Campbell | AngioDynamics | 53 | |
| Don OCallaghan | West Pharmaceutical Services | N/A | |
| Jan Verstreken | Hologic | 56 | |
| Virginia Sanzone | ICU Medical | 49 | |
| Roy Galvin | Haemonetics | 54 | |
| Kim Seabury | AngioDynamics | 57 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| David Helsel | AngioDynamics | 60 | |
| Roger Graham | Teleflex Incorporated | N/A | |
| Lisa Kudlacz | Teleflex Incorporated | N/A | |
Management Performance
| Return On Equity | 0.0563 | ||||
| Return On Asset | 0.0325 |
Becton Dickinson Leadership Team
Elected by the shareholders, the Becton Dickinson's board of directors comprises two types of representatives: Becton Dickinson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Becton. The board's role is to monitor Becton Dickinson's management team and ensure that shareholders' interests are well served. Becton Dickinson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Becton Dickinson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Reidy, Chief Financial Officer, Executive Vice President, Chief Administrative Officer | ||
| Denise Fleming, Executive Officer | ||
| Rebecca Rimel, Independent Director | ||
| Alberto Mas, Executive Vice President and President - Life Sciences Segment | ||
| Thomas Spoerel, Senior Vice President, Controller and Chief Accounting Officer, Principal Accounting Officer | ||
| Michelle Quinn, Executive Counsel | ||
| Claire Fraser, Independent Director | ||
| Carla Burigatto, Senior Officer | ||
| Alexandre Conroy, Executive Vice President, Chief Integrated Supply Chain Officer | ||
| Shana Neal, Executive Officer | ||
| Ami Simunovich, Regulatory Quality | ||
| Christopher CPA, Executive CFO | ||
| Ching leong, Executive Vice President and President Greater Asia | ||
| Jeffrey Henderson, Independent Director | ||
| Elizabeth McCombs, Executive Officer | ||
| Bertram Scott, Independent Director | ||
| John DeFord, Executive Vice President, Chief Technology Officer | ||
| FACC MD, Chief VP | ||
| Greg Rodetis, Head Relations | ||
| Samrat Esq, Public Devel | ||
| Francesca DeMartino, VP Relations | ||
| Christopher Jones, Independent Director | ||
| David Hickey, Executive Vice President and President, Life Sciences Segment | ||
| Antoinette Segreto, Senior Taxes | ||
| Claire Pomeroy, Independent Director | ||
| Betty Larson, Executive Vice President- Human Resources, Chief Human Resources | ||
| Patrick Kaltenbach, Executive Vice President, President - Life Sciences | ||
| Michael Garrison, Executive segment | ||
| Catherine Burzik, Independent Director | ||
| James Borzi, Executive Vice President - Global Operations, Chief Supply Chain Officer | ||
| William Brown, Independent Director | ||
| Claudia Curtis, Chief VP | ||
| Charles Bodner, Senior Vice President Corporate Finance, and Chief Accounting Officer and Principal Accounting Officer | ||
| R Eckert, Independent Director | ||
| Simon Campion, Executive Vice President and President BD Interventional Segment | ||
| Carrie Byington, Independent Director | ||
| Roland Goette, Executive Vice President and Presidentident - EMEA | ||
| Vincent Forlenza, Chairman, CEO and President and Chairman of Executive Committee | ||
| James Lim, Executive Vice President and President, Greater Asia | ||
| Christopher DelOrefice, Chief Financial Officer, Executive Vice President | ||
| Samrat Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel | ||
| Antoine Ezell, Executive Vice President and Presidentident, North America and Chief Marketing Officer | ||
| Thomas Polen, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer | ||
| David Melcher, Independent Director | ||
| Marshall Larsen, Lead Independent Director | ||
| Troy Kirkpatrick, VP PR | ||
| Timothy Ring, Independent Director |
Becton Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Becton Dickinson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0563 | ||||
| Return On Asset | 0.0325 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 82.1 B | ||||
| Shares Outstanding | 289.12 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 91.74 % | ||||
| Number Of Shares Shorted | 2.11 M | ||||
| Price To Earning | 45.86 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Becton Stock Analysis
When running Becton Dickinson's price analysis, check to measure Becton Dickinson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Becton Dickinson is operating at the current time. Most of Becton Dickinson's value examination focuses on studying past and present price action to predict the probability of Becton Dickinson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Becton Dickinson's price. Additionally, you may evaluate how the addition of Becton Dickinson to your portfolios can decrease your overall portfolio volatility.